Hengrui, which made $2.5 billion in sales last year, invests twice as much as any other pharma in R&D, and its investments are paying off: It’s China’s largest pharmaceutical company and a leader in innovation. China’s plan to bulk-purchase generic drugs in 2020 will drive down industry prices, but analysts say only 1% to 2% of Jiangsu’s revenue will be impacted, while competitors in its peer group will be more exposed.
Subscribe to Fortune’s Brainstorm Health Daily newsletter, where we monitor advances in healthcare and biopharma.
|Revenues ($M) (Past 12 Months)||$2,884|
|Profits ($M) (Past 12 Months)||$669|
|Market Value as of Oct. 9, 2019 ($M)||$48,796|
Refinitiv Sustainable Leadership Monitor
The Sustainable Leadership Monitor is independent and separate from BCG and the Future 50.